Kisspeptin and Female Sexual Arousal

Female Sexual Health Peptides

32 women with HSDD

In a double-blind crossover trial, kisspeptin modulated sexual brain processing and increased self-reported feelings of sexiness in premenopausal women with hypoactive sexual desire disorder.

Mills et al., JAMA Network Open, 2022

Mills et al., JAMA Network Open, 2022

View as image

Kisspeptin is best known as the peptide that triggers puberty and controls reproductive hormone release through the GnRH axis. But a series of fMRI studies published between 2017 and 2023 revealed something unexpected: kisspeptin also modulates how the brain processes sexual stimuli, attraction cues, and emotional responses. In women with hypoactive sexual desire disorder (HSDD), the most common female sexual dysfunction, kisspeptin administration altered activity in brain regions tied to self-monitoring, arousal, and sexual aversion. These neuroimaging findings position kisspeptin as something distinct from existing HSDD treatments like bremelanotide: rather than directly activating desire pathways, it appears to quiet the brain circuits that inhibit sexual response. For the broader role of peptides in female sexual function, see the oxytocin and female sexual response pillar article.

What Kisspeptin Does in the Brain

Kisspeptin is a neuropeptide encoded by the KISS1 gene, first identified for its metastasis-suppressor properties in melanoma cells. Its reproductive role was discovered when loss-of-function mutations in the kisspeptin receptor (KISS1R) were found to cause hypogonadotropic hypogonadism, a condition of absent puberty and infertility.^[1]

In the hypothalamus, kisspeptin neurons in the arcuate nucleus and anteroventral periventricular nucleus directly stimulate GnRH neurons to control luteinizing hormone (LH) pulsatility and downstream sex steroid production. This kisspeptin-GnRH-gonadotropin pathway is the central regulatory circuit of mammalian reproduction.^[1] For more on this axis, see Kisspeptin and GnRH: How One Peptide Controls Your Reproductive Hormones.

The finding that changed the conversation came from receptor mapping studies: KISS1R is expressed not only in the hypothalamus but in limbic and paralimbic brain regions, including the amygdala, hippocampus, cingulate cortex, and thalamus.^[2] These are the brain areas that process emotion, reward, fear, and sexual arousal. If kisspeptin receptors exist there, kisspeptin might do something there.

The Landmark Study: Sexual Brain Processing in Healthy Men (2017)

The first human neuroimaging study of kisspeptin and sexual processing was published in the Journal of Clinical Investigation in 2017 by Comninos et al. at Imperial College London.^[3]

Twenty-nine healthy heterosexual men received either kisspeptin-54 or saline infusion in a double-blind, placebo-controlled, two-way crossover design while undergoing fMRI. The researchers presented three categories of visual stimuli: sexual images (couples in intimate situations), couple-bonding images (nonsexual romantic scenes), and negative emotional images.

Kisspeptin enhanced limbic brain activity specifically in response to sexual stimuli. The activated regions included the amygdala, cingulate cortex, globus pallidus, posterior thalamus, and putamen. This enhancement was selective: kisspeptin did not change brain responses to nonsexual couple-bonding images or negative emotional stimuli. Kisspeptin also reduced self-reported negative mood on psychometric testing.

The selectivity matters. It suggests kisspeptin is not a general mood enhancer or a nonspecific brain activator. It appears to specifically amplify the neural circuits that process sexual information. The study provided the first human evidence that a reproductive hormone could integrate with the emotional brain during sexual processing.

Kisspeptin in Women With HSDD (2022)

The study most relevant to female sexual arousal was published in JAMA Network Open in 2022 by Mills et al.^[4] This was a randomized, double-blind, placebo-controlled crossover trial in 32 premenopausal women diagnosed with HSDD, conducted at Imperial College London from October 2020 to April 2021.

Brain Activity Changes

During viewing of erotic videos, kisspeptin produced two distinct patterns of brain activity change:

Deactivation of the left inferior frontal gyrus. This region is involved in response inhibition, self-monitoring, and negative internal monologue. Its deactivation during sexual stimuli suggests kisspeptin may reduce the self-critical cognitive processes that interfere with sexual arousal. In HSDD, excessive self-monitoring during sexual situations is a recognized clinical feature. The inferior frontal gyrus deactivation offers a neural mechanism for how kisspeptin might bypass this inhibition.

Activation of the right postcentral and supramarginal gyrus. These areas process somatosensory information and bodily awareness. Their increased activation during sexual stimuli could reflect enhanced awareness of physical arousal cues, bridging the gap between brain processing and bodily sexual response.

Reduced Sexual Aversion

Kisspeptin increased activation in the posterior cingulate cortex when participants viewed male faces. Higher posterior cingulate activation correlated with reduced self-reported sexual aversion scores. The posterior cingulate is involved in self-referential processing and has been linked to feelings of romantic love in other neuroimaging research. This finding suggests kisspeptin may shift the brain's default response to potential sexual partners from avoidance toward approach.

Behavioral Outcomes

Participants reported increased "feeling sexy" scores during kisspeptin administration compared to placebo. Kisspeptin also raised LH by a mean of 2.75 IU/L and FSH by 0.37 IU/L over 75 minutes, confirming the expected reproductive hormone response. No effect on circulating estradiol, progesterone, or testosterone was observed during the study window. No side effects were reported.

Extending the Evidence: Attraction Processing and Male HSDD

Two additional fMRI studies from the same group provide context for the female HSDD findings.

Olfactory and Visual Attraction (2020)

Comninos et al. tested whether kisspeptin modulates brain responses to nonsexual attraction cues in 33 healthy men.^[5] Kisspeptin enhanced brain activity in the amygdala, caudate, putamen, and thalamus in response to a feminine olfactory cue (a commercial perfume). It also enhanced brain responses to attractive female faces. Kisspeptin increased penile tumescence in response to the olfactory cue and increased attraction scores for faces. This study broadened kisspeptin's role beyond explicit sexual stimuli to include the subtler cues of interpersonal attraction.

Male HSDD (2023)

Mills et al. conducted a parallel trial to the female HSDD study, testing kisspeptin in 32 men with HSDD.^[6] Kisspeptin modulated sexual brain processing, enhanced penile tumescence to erotic videos, and increased happiness scores. The fact that kisspeptin produced measurable effects in both female and male HSDD populations, through somewhat different neural patterns, supports a broad role in sexual desire circuitry rather than a sex-specific mechanism.

How Kisspeptin Differs From Bremelanotide

The only FDA-approved peptide treatment for female HSDD is bremelanotide (Vyleesi), a melanocortin-4 receptor agonist that works through a different pathway. Bremelanotide activates dopaminergic circuits in the medial preoptic area to directly stimulate desire. It is injected subcutaneously before anticipated sexual activity and causes nausea in approximately 40% of users.

Kisspeptin appears to work through a complementary but distinct mechanism: reducing inhibitory brain activity (self-monitoring, response inhibition, sexual aversion) rather than directly amplifying excitatory desire signals. If both mechanisms are validated, they could theoretically be combined, one reducing the brakes while the other presses the accelerator. This remains speculative; no combination study has been conducted.

Limitations of the Current Evidence

The kisspeptin neuroimaging evidence has several constraints that must be acknowledged:

Single research group. All five key neuroimaging studies come from the Dhillo lab at Imperial College London. The findings are internally consistent and published in high-impact journals (JCI, JAMA Network Open), but independent replication by a separate group has not yet occurred.

Small sample sizes. The studies enrolled 29 to 33 participants each. While adequate for detecting large fMRI signal changes, they are underpowered for detecting subtle effects or for subgroup analyses.

Acute administration only. All studies used single-session IV kisspeptin infusion. Whether repeated dosing produces sustained changes in sexual brain processing, or whether tolerance develops, is unknown.

Brain activity is not behavior. fMRI measures blood-oxygen-level-dependent signal changes, a proxy for neural activity. The studies show kisspeptin changes how the brain responds to sexual stimuli, but the behavioral measures (self-reported "feeling sexy," attraction scores) are subjective and assessed during artificial laboratory conditions. Whether these brain changes translate to improved sexual function in real-world settings has not been tested.

Hormone effects are transient. In the female HSDD trial, kisspeptin raised LH and FSH but did not change circulating sex steroids within the 75-minute window. The brain effects may operate through direct kisspeptin receptor signaling in limbic regions rather than through downstream hormone changes, but this has not been conclusively demonstrated.

No phase 2 or phase 3 trials exist. All published work is mechanistic and exploratory. The leap from "kisspeptin changes brain responses to erotic videos during an fMRI scan" to "kisspeptin treats HSDD" requires clinical trials measuring sexual function outcomes over weeks or months.

Therapeutic Potential and Open Questions

Kisspeptin's therapeutic profile, if confirmed, would differ from existing options for HSDD. It was well-tolerated with no reported side effects across all published trials. It has a short half-life (approximately 28 minutes for kisspeptin-54), which could be advantageous for on-demand use but would require formulation optimization for practical clinical application.^[7]

The reproductive biology of kisspeptin also matters. Because kisspeptin stimulates LH and FSH release, chronic administration could theoretically disrupt menstrual cycles or ovarian function. Whether intermittent, on-demand dosing would avoid this problem is a pharmacological question that has not been addressed.^[8]

The most intriguing question is whether kisspeptin's mechanism of action, reducing inhibitory brain processing during sexual contexts, addresses a root cause of HSDD that current treatments miss. Cognitive behavioral models of HSDD emphasize the role of negative cognitive interference (self-criticism, performance anxiety, body image concerns) in suppressing desire. If kisspeptin quiets the neural substrate of this interference, it would represent a fundamentally different therapeutic approach from directly stimulating desire pathways.

For the broader landscape of peptide therapeutics for female sexual dysfunction, kisspeptin research represents the most active area of investigation after bremelanotide.

The Bottom Line

fMRI studies demonstrate that kisspeptin modulates sexual brain processing in both healthy individuals and patients with HSDD. In women with HSDD, kisspeptin deactivated self-monitoring brain regions and increased feelings of sexiness. All current evidence comes from a single research group using acute IV infusions in small samples. No clinical efficacy trials exist. The mechanism, reducing inhibitory brain processing rather than directly stimulating desire, is scientifically distinct from existing treatments but remains to be validated in real-world sexual function outcomes.

Frequently Asked Questions

What is kisspeptin and what does it do?

Kisspeptin is a neuropeptide produced by neurons in the hypothalamus that controls reproductive hormone release through the GnRH axis. It triggers puberty, regulates menstrual cycles, and controls fertility. Recent fMRI studies show it also modulates how the brain processes sexual stimuli, enhancing limbic activity to sexual images while reducing activity in self-monitoring regions. Kisspeptin receptors are found in the amygdala, hippocampus, cingulate cortex, and thalamus, areas involved in emotion, reward, and sexual arousal.

Can kisspeptin treat low sexual desire in women?

A 2022 randomized trial in 32 women with hypoactive sexual desire disorder found that kisspeptin administration altered sexual brain processing on fMRI and increased self-reported feelings of sexiness compared to placebo (Mills et al., JAMA Network Open). However, this was a single-session mechanistic study, not a clinical efficacy trial. No phase 2 or phase 3 trials have tested whether kisspeptin improves sexual function over weeks or months. The findings are promising but preliminary.

How does kisspeptin affect the brain during sexual arousal?

In fMRI studies, kisspeptin deactivated the left inferior frontal gyrus, a brain region involved in response inhibition and self-monitoring, while activating the postcentral and supramarginal gyrus, areas that process bodily awareness. In healthy men, it enhanced activity in the amygdala, cingulate, globus pallidus, thalamus, and putamen specifically during viewing of sexual images. The pattern suggests kisspeptin reduces cognitive inhibition of sexual response while enhancing sensory processing of arousal cues.

What is the difference between kisspeptin and bremelanotide for HSDD?

Bremelanotide (Vyleesi) is FDA-approved for HSDD and works by activating melanocortin-4 receptors in dopaminergic circuits to directly stimulate desire. Kisspeptin appears to work differently: it reduces activity in brain regions that inhibit sexual response (self-monitoring, sexual aversion) rather than directly amplifying desire. Bremelanotide causes nausea in about 40% of users. Kisspeptin showed no reported side effects in clinical trials, though these were small mechanistic studies, not efficacy trials.

Is kisspeptin safe?

Across all published neuroimaging studies (totaling over 125 participants in men and women), kisspeptin-54 administered as IV infusion was well-tolerated with no reported side effects. It transiently raised LH and FSH levels, consistent with its known reproductive hormone effects. Long-term safety data do not exist. Because kisspeptin stimulates gonadotropin release, chronic use could theoretically affect menstrual cycles or ovarian function. Safety in repeated or chronic dosing has not been studied.

When will kisspeptin be available as a treatment?

Kisspeptin is not approved as a treatment for any condition and is not available as a prescription medication. All published research is mechanistic (fMRI brain imaging studies), not clinical efficacy trials. Phase 2 and phase 3 trials testing whether kisspeptin improves real-world sexual function have not been published. The peptide's short half-life (approximately 28 minutes) also requires formulation development before practical clinical use. No timeline for regulatory approval exists.